Univariate and multivariate Cox regression analyses of sIL-6r concentration and other baseline prognostic factors
| Prognostic factor . | n/N (%) . | Overall survival . | |
|---|---|---|---|
| HR (95% CI) . | P* . | ||
| Univariate | |||
| Age, ≥ 65 y | 167/626 (27) | 1.69 (1.21, 2.37) | .002 |
| Albumin < 3.5 g/dL | 204/623 (33) | 1.65 (1.18, 2.31) | .003 |
| β2-microglobulin ≥ 3.5 mg/L | 308/622 (50) | 2.12 (1.51, 2.98) | < .001 |
| β2-microglobulin ≥ 5.5 mg/L | 152/622 (24) | 2.67 (1.91, 3.73) | < .001 |
| Creatinine ≥ 2 mg/dL | 51/621 (8) | 2.21 (1.39, 3.51) | < .001 |
| CRP ≥ 8 mg/L | 184/623 (30) | 1.41 (1.01, 1.97) | .046 |
| Hemoglobin < 10 g/dL | 194/624 (31) | 1.67 (1.20, 2.33) | .002 |
| LDH ≥ 190 U/L | 145/624 (23) | 1.81 (1.29, 2.54) | < .001 |
| Cytogenetic abnormalities | 224/618 (36) | 2.11 (1.52, 2.93) | < .001 |
| GEP70 high-risk | 81/626 (13) | 3.33 (2.33, 4.78) | < .001 |
| CD-1 subgroup | 41/625 (7) | 1.17 (0.63, 2.16) | .617 |
| CD-2 subgroup | 89/625 (14) | 0.71 (0.43, 1.18) | .183 |
| HY subgroup | 196/625 (31) | 0.79 (0.55, 1.14) | .205 |
| LB subgroup | 66/625 (11) | 0.84 (0.47, 1.48) | .537 |
| MF subgroup | 36/625 (6) | 2.13 (1.27, 3.59) | .004 |
| MS subgroup | 77/625 (12) | 0.81 (0.48, 1.39) | .447 |
| MY subgroup | 50/625 (8) | 0.98 (0.55, 1.73) | .936 |
| PR subgroup | 70/625 (11) | 1.74 (1.12, 2.69) | .014 |
| GEP proliferation index ≥ 10 | 52/626 (8) | 2.64 (1.74, 4.00) | < .001 |
| TP53 deletion | 108/626 (17) | 1.40 (0.90, 2.18) | .133 |
| Amplification in 1q21 | 237/626 (38) | 1.58 (1.15, 2.19) | .005 |
| sIL6r ≥ 81.5 ng/ml | 129/626 (21) | 2.26 (1.61, 3.18) | < .001 |
| Multivariate† (total R2 = 26.1%) | |||
| Age, ≥ 65 y | 164/608 (27) | 1.70 (1.21, 2.39) | .002 |
| β2-microglobulin ≥ 5.5 mg/L | 148/608 (24) | 1.99 (1.38, 2.86) | < .001 |
| Cytogenetic abnormalities | 222/608 (37) | 1.58 (1.11, 2.24) | .011 |
| GEP proliferation index ≥ 10 | 51/608 (8) | 2.03 (1.30, 3.16) | .002 |
| sIL6r ≥ 81.5 ng/mL | 124/608 (20) | 1.52 (1.05, 2.21) | .026 |
| Prognostic factor . | n/N (%) . | Overall survival . | |
|---|---|---|---|
| HR (95% CI) . | P* . | ||
| Univariate | |||
| Age, ≥ 65 y | 167/626 (27) | 1.69 (1.21, 2.37) | .002 |
| Albumin < 3.5 g/dL | 204/623 (33) | 1.65 (1.18, 2.31) | .003 |
| β2-microglobulin ≥ 3.5 mg/L | 308/622 (50) | 2.12 (1.51, 2.98) | < .001 |
| β2-microglobulin ≥ 5.5 mg/L | 152/622 (24) | 2.67 (1.91, 3.73) | < .001 |
| Creatinine ≥ 2 mg/dL | 51/621 (8) | 2.21 (1.39, 3.51) | < .001 |
| CRP ≥ 8 mg/L | 184/623 (30) | 1.41 (1.01, 1.97) | .046 |
| Hemoglobin < 10 g/dL | 194/624 (31) | 1.67 (1.20, 2.33) | .002 |
| LDH ≥ 190 U/L | 145/624 (23) | 1.81 (1.29, 2.54) | < .001 |
| Cytogenetic abnormalities | 224/618 (36) | 2.11 (1.52, 2.93) | < .001 |
| GEP70 high-risk | 81/626 (13) | 3.33 (2.33, 4.78) | < .001 |
| CD-1 subgroup | 41/625 (7) | 1.17 (0.63, 2.16) | .617 |
| CD-2 subgroup | 89/625 (14) | 0.71 (0.43, 1.18) | .183 |
| HY subgroup | 196/625 (31) | 0.79 (0.55, 1.14) | .205 |
| LB subgroup | 66/625 (11) | 0.84 (0.47, 1.48) | .537 |
| MF subgroup | 36/625 (6) | 2.13 (1.27, 3.59) | .004 |
| MS subgroup | 77/625 (12) | 0.81 (0.48, 1.39) | .447 |
| MY subgroup | 50/625 (8) | 0.98 (0.55, 1.73) | .936 |
| PR subgroup | 70/625 (11) | 1.74 (1.12, 2.69) | .014 |
| GEP proliferation index ≥ 10 | 52/626 (8) | 2.64 (1.74, 4.00) | < .001 |
| TP53 deletion | 108/626 (17) | 1.40 (0.90, 2.18) | .133 |
| Amplification in 1q21 | 237/626 (38) | 1.58 (1.15, 2.19) | .005 |
| sIL6r ≥ 81.5 ng/ml | 129/626 (21) | 2.26 (1.61, 3.18) | < .001 |
| Multivariate† (total R2 = 26.1%) | |||
| Age, ≥ 65 y | 164/608 (27) | 1.70 (1.21, 2.39) | .002 |
| β2-microglobulin ≥ 5.5 mg/L | 148/608 (24) | 1.99 (1.38, 2.86) | < .001 |
| Cytogenetic abnormalities | 222/608 (37) | 1.58 (1.11, 2.24) | .011 |
| GEP proliferation index ≥ 10 | 51/608 (8) | 2.03 (1.30, 3.16) | .002 |
| sIL6r ≥ 81.5 ng/mL | 124/608 (20) | 1.52 (1.05, 2.21) | .026 |
HR indicates hazard ratio; 95% CI, 95% confidence interval; CRP, C-reactive protein; and LDH, lactate dehydrogenase.
Wald χ2 test in Cox regression model. All univariate P values are reported regardless of significance.
Multivariate model uses stepwise selection with entry level 0.1 and variable remains if it meets the .05 level. The multivariate model includes all variables with univariate P < .15, except the GEP 70-gene model variable in the model.